Combating breast cancer with non-steroidal aromatase inhibitors (NSAIs): Understanding the chemico-biological interactions through comparative SAR/QSAR study
10.1016/j.ejmech.2017.05.041
Crossref journal-article
Elsevier BV
European Journal of Medicinal Chemistry (78)
Bibliography

Adhikari, N., Amin, Sk. A., Saha, A., & Jha, T. (2017). Combating breast cancer with non-steroidal aromatase inhibitors (NSAIs): Understanding the chemico-biological interactions through comparative SAR/QSAR study. European Journal of Medicinal Chemistry, 137, 365–438.

Authors 4
  1. Nilanjan Adhikari (first)
  2. Sk. Abdul Amin (additional)
  3. Achintya Saha (additional)
  4. Tarun Jha (additional)
References 165 Referenced 60
  1. {'key': '10.1016/j.ejmech.2017.05.041_bib1', 'series-title': 'Breast Cancer Facts & Figures\xa02015-2016', 'author': 'American Cancer Society', 'year': '2015'} / Breast Cancer Facts & Figures 2015-2016 by American Cancer Society (2015)
  2. T. Jha, N. Adhikari, A. K. Halder, A. Saha, Ligand- and structure-based drug design of non-steroidal aromatase inhibitors (NSAIs) in breast cancer, in: K. Roy (Ed.), Quantitative Structure-activity Relationships in Drug Design, Predictive Toxicology, and Risk Assessment, IGI Global, Hershey PA, USA, pp. 400–470. (10.4018/978-1-4666-8136-1.ch011)
  3. {'key': '10.1016/j.ejmech.2017.05.041_bib3', 'first-page': '10', 'article-title': 'Cancer statistics, 2012, CA: a can', 'volume': '62', 'author': 'Siegel', 'year': '2012', 'journal-title': 'J.\xa0Clin.'} / J. Clin. / Cancer statistics, 2012, CA: a can by Siegel (2012)
  4. 10.1186/1477-7827-12-66 / Reprod. Biol. Endocrinol. / The role of hormones and aromatase inhibitors on breast tumor growth and general health in a postmenopausal mouse model by Arumugam (2014)
  5. {'key': '10.1016/j.ejmech.2017.05.041_bib5', 'first-page': '1', 'article-title': 'US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status', 'volume': '106', 'author': 'Howlader', 'year': '2014', 'journal-title': 'J.\xa0Nat. Can. Inst.'} / J. Nat. Can. Inst. / US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status by Howlader (2014)
  6. 10.1136/esmoopen-2016-000062 / ESMO Open / Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant by Kumler (2016)
  7. 10.1016/S0093-7754(03)00302-6 / Semin. Oncol. / Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer by Miller (2003)
  8. {'key': '10.1016/j.ejmech.2017.05.041_bib8', 'first-page': '101', 'article-title': 'On the treatment of inoperable cases of carcinoma of the mamma: suggestion for a new method of treatment, with illustrative cases', 'volume': '148', 'author': 'Beatson', 'year': '1896', 'journal-title': 'Lancet'} / Lancet / On the treatment of inoperable cases of carcinoma of the mamma: suggestion for a new method of treatment, with illustrative cases by Beatson (1896)
  9. 10.2174/1568011043352669 / Curr. Med. Chem. Anti-Can. Agents / Aromatase inhibitors: a new paradigm in breast cancer treatment by Murthy (2004)
  10. 10.2174/156802606776173483 / Curr. Top. Med. Chem. / Estrogen receptors as therapeutic targets in breast cancer by Ariazi (2006)
  11. 10.1210/er.2004-0015 / Endocrinol. Rev. / Aromatase inhibitors in the treatment of breast cancer by Brueggemeier (2005)
  12. {'key': '10.1016/j.ejmech.2017.05.041_bib12', 'first-page': '123', 'article-title': 'The selective estrogen enzyme modulators in breast cancer: a review', 'volume': '1654', 'author': 'Pasqualini', 'year': '2004', 'journal-title': 'Biochimica Biophysica Acta'} / Biochimica Biophysica Acta / The selective estrogen enzyme modulators in breast cancer: a review by Pasqualini (2004)
  13. 10.1016/S0968-0896(97)10053-0 / Bioorg. Med. Chem. / Comparative molecular field analysis of non-steroidal aromatase inhibitors: an extended model for two different structural classes by Recanatini (1998)
  14. 10.1016/j.jsbmb.2005.04.021 / J. Steroid Biochem. Mol. Biol. / Aromatase inhibitors: future directions by Osborne (2005)
  15. 10.1016/j.jsbmb.2006.09.002 / J. Steroid Biochem. Mol. Biol. / Aromatase and breast cancer by Brodie (2006)
  16. {'key': '10.1016/j.ejmech.2017.05.041_bib16', 'first-page': '34', 'article-title': 'Aromatase inhibitors in advanced breast cancer', 'volume': '99', 'author': 'Spinelli', 'year': '2008', 'journal-title': 'Recent. Prog. Med.'} / Recent. Prog. Med. / Aromatase inhibitors in advanced breast cancer by Spinelli (2008)
  17. 10.1007/s12032-007-9019-x / Med. Oncol. / Aromatase inhibitors: Past, present and future in breast cancer therapy by Dutta (2008)
  18. 10.2174/138955708784534472 / Mini Rev. Med. Chem. / Aromatase inhibitors:A new reality for the adjuvant endocrine treatment of early-stage breast cancer in postmenopausal women by Colozza (2008)
  19. 10.2174/156802608784911590 / Curr. Top. Med. Chem. / From non-steroidal aromatase inhibitors to multifunctional drug candidates: classic and innovative strategies for the treatment of breast cancer by Gobbi (2008)
  20. 10.1016/j.ejmech.2009.05.003 / Eur. J. Med. Chem. / An efficient steroid pharmacophore based strategy to identify new aromatase inhibitors by Neves (2009)
  21. 10.1002/med.10010 / Med. Res. Rev. / Non-steroidal aromatase inhibitors: recent advances by Recanatini (2002)
  22. 10.1126/science.1096361 / Science / The many roles of computation in drug discovery by Jorgensen (2004)
  23. 10.1007/978-1-61779-012-6_2 / Methods Mol. Biol. / Computer-aided drug discovery and development by Zhang (2011)
  24. 10.1038/nrd941 / Nat. Rev. Drug Discov. / Integration of virtual and high-throughput screening by Bajorath (2002)
  25. 10.1038/nchembio.1199 / Nat. Chem. Biol. / Target identification and mechanism of action in chemical biology and drug discovery by Schenone (2013)
  26. 10.1111/j.1476-5381.2010.01127.x / Br. J. Pharmacol. / Principles of early drug discovery by Hughes (2011)
  27. 10.1021/jm8010096 / J. Med. Chem. / Discovery of multi-target inhibitors by combining molecular docking with common pharmacophore matching by Wei (2008)
  28. 10.1038/srep16924 / Sci. Rep. / Large-scale computational screening identifies first in class multitarget inhibitor of EGFR kinase and BRD4 by allen (2015)
  29. 10.1021/cr0780210 / Chem. Rev. / Camptothecins: a SAR/QSAR study by Verma (2009)
  30. 10.1021/ci6002043 / J. Chem. Inf. Model / Parallel screening: a novel concept in pharmacophore modeling and virtual screening by Steindl (2006)
  31. 10.1016/j.bmcl.2016.10.058 / Bioorg. Med. Chem. Lett. / First molecular modeling report on novel arylpyrimidine kynurenine monooxygenase inhibitors through multi-QSAR analysis against Huntington's disease: a proposal to chemists! by Amin (2016)
  32. {'key': '10.1016/j.ejmech.2017.05.041_bib32', 'first-page': '1', 'article-title': 'The history and development of quantitative structure-activity relationships', 'volume': '1', 'author': 'Dearden', 'year': '2016', 'journal-title': 'Int. J. Quant. Struct. Prop. Relat.'} / Int. J. Quant. Struct. Prop. Relat. / The history and development of quantitative structure-activity relationships by Dearden (2016)
  33. 10.1016/S0968-0896(00)00203-0 / Bioorg. Med. Chem. / Linking CoMFA and protein homology models of enzyme-inhibitor interactions: an application to non-steroidal aromatase inhibitors by Cavalli (2000)
  34. 10.1021/ci050237k / J. Chem. Inf. Model / Pharmacophore modeling and in silico screening for new P450 19 (aromatase) inhibitors by Schuster (2006)
  35. 10.1007/s11030-008-9077-9 / Mol. Divers / Pharmacophore mapping of flavones derivatives for aromatase inhibition by Nagar (2008)
  36. 10.1016/j.bmc.2008.08.046 / Bioorg. Med. Chem. / CYP19 (aromatase): exploring the scaffold flexibility for novel selective inhibitors by Castellano (2008)
  37. 10.1021/jm800945c / J. Med. Chem. / Fast three dimensional Pharmacophore virtual screening of new potent non-steroid aromatase inhibitors by Neves (2009)
  38. 10.1016/j.ejmech.2010.06.033 / Eur. J. Med. Chem. / Exploring benzcyclo derivatives as potent aromatase inhibitors using ligand based modeling studies by Nagar (2010)
  39. 10.1002/jcc.21528 / J. Comput. Chem. / Modeling of diarylalkyl-imidazole and diarylalkyl-triazole derivatives as potent aromatase inhibitors for treatment of hormone-dependent cancer by Nagar (2010)
  40. 10.1016/j.bmcl.2010.03.113 / Bioorg. Med. Chem. Lett. / Pharmacophore modeling strategies for the development of novel non-steroidal inhibitors of human aromatase (CYP19) by Muftuoglu (2010)
  41. 10.1111/j.1747-0285.2011.01277.x / Chem. Biol. Drug Des. / Molecular modeling evaluation of non-steroidal aromatase inhibitors by Narayana (2012)
  42. 10.1007/s11030-013-9462-x / Mol. Divers / Exploring the chemical space of aromatase inhibitors by Nantasenamat (2013)
  43. 10.1016/j.ejmech.2013.08.015 / Eur. J. Med. Chem. / QSAR modeling of aromatase inhibitory activity of 1-substituted 1, 2, 3-triazole analogs of letrozole by Nantasenamat (2013)
  44. 10.1016/j.chemolab.2014.07.017 / Chemom. Intell. Lab. Sys / Large-scale QSAR study of aromatase inhibitors using SMILES-based descriptors by Worachartcheewan (2014)
  45. 10.1007/s00044-014-1257-9 / Med. Chem. Res. / Pharmacophore modeling, virtual screening, and 3D-QSAR studies on a series of non-steroidal aromatase inhibitors by Xie (2015)
  46. 10.1016/S0021-9258(19)36937-6 / J. Biol. Chem. / Core glycosylation of cytochrome P-450(arom). Evidence for localization of N terminus of microsomal cytochrome P-450 in the lumen by Shimozawa (1993)
  47. {'key': '10.1016/j.ejmech.2017.05.041_bib47', 'first-page': '1617', 'article-title': 'Functional domains of human aromatase cytochrome P450 characterized by linear alignment and site-directed mutagenesis', 'volume': '7', 'author': 'Amarneh', 'year': '1993', 'journal-title': 'Mol. Endocrinol. Baltim. Md.)'} / Mol. Endocrinol. Baltim. Md.) / Functional domains of human aromatase cytochrome P450 characterized by linear alignment and site-directed mutagenesis by Amarneh (1993)
  48. 10.1038/nature07614 / Nature / Structural basis for androgen specificity and oestrogen synthesis in human aromatase by Ghosh (2009)
  49. 10.1016/j.jsbmb.2009.09.012 / J. Steroid Biochem. Mol. Biol. / X-ray structure of human aromatase reveals an androgen-specific active site by Ghosh (2010)
  50. 10.1016/S0960-0760(98)00022-3 / J. Steroid Biochem. Mol. Biol. / Aromatase inhibitors in advanced breast cancer: mechanism of action and clinical implications by Brodie (1998)
  51. 10.1210/endo.142.11.8547 / Endocrinol / Aromatase and the regulation of estrogen biosynthesis-some new perspectives by Simpson (2001)
  52. 10.1016/S0021-9258(18)61364-X / J. Biol. Chem. / Purification and characterization of human placental aromatase cytochrome P450 by Kellis (1987)
  53. {'key': '10.1016/j.ejmech.2017.05.041_bib53', 'first-page': '342', 'article-title': 'Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis', 'volume': '15', 'author': 'Simpson', 'year': '1994', 'journal-title': 'Endocr. Rev.'} / Endocr. Rev. / Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis by Simpson (1994)
  54. {'key': '10.1016/j.ejmech.2017.05.041_bib54', 'first-page': '337', 'article-title': 'Detection of intratumoral aromatase in breast carcinomas, an immunohistochemical study with clinico-pathologic correlation', 'volume': '140', 'author': 'Esteban', 'year': '1992', 'journal-title': 'Am. J. Pathol.'} / Am. J. Pathol. / Detection of intratumoral aromatase in breast carcinomas, an immunohistochemical study with clinico-pathologic correlation by Esteban (1992)
  55. {'key': '10.1016/j.ejmech.2017.05.041_bib55', 'article-title': 'Closing remarks to the conference, aromatase: new perspectives for breast cancer', 'volume': '42', 'author': 'Lipton', 'year': '1982', 'journal-title': 'Cancer Res.'} / Cancer Res. / Closing remarks to the conference, aromatase: new perspectives for breast cancer by Lipton (1982)
  56. 10.3109/14756368809040728 / J. Enz. Inhib. / Structure-activity relationships for non-steroidal inhibitors of aromatase by Banting (1988)
  57. 10.1021/jm00173a001 / J. Med. Chem. / Mechanism and inhibition of cytochrome P450 aromatase by Cole (1990)
  58. 10.1007/BF00682739 / Breast Cancer Res. Treat. / Aromatase inhibitors mechanisms of steroidal inhibitors by Brueggemeier (1994)
  59. 10.1016/S0960-0760(99)00051-5 / J. Steroid Biochem. Mol. Biol. / Aromatase and its inhibitors by Brodie (1999)
  60. 10.1016/S0039-128X(99)00104-X / Steroids / Aromatase inhibitors and their application in breast cancer treatment by Brodie (2000)
  61. 10.1634/theoncologist.11-6-553 / Oncol. / Aromatase inhibitors in breast cancer: an overview by Altundag (2006)
  62. 10.2174/157339407780126656 / Curr. Cancer Ther. Rev. / Aromatase inhibitors for treatment of breast cancer by Benson (2007)
  63. 10.1177/1060028014548416 / Ann. Pharmacother. / Aromatase inhibitors in breast cancer prevention by Olin (2014)
  64. 10.1586/14737140.2014.882233 / Exp. Rev. Antican. Ther. / Advances in mechanisms of resistance to aromatase inhibitors by Chumsri (2014)
  65. 10.1530/ERC-13-0269 / Endocr. Relat. Cancer / Aromatase inhibitors in the breast cancer clinic: focus on exemestane by van Asten (2014)
  66. {'key': '10.1016/j.ejmech.2017.05.041_bib66', 'first-page': '54', 'article-title': 'Nonsteroidal aromatase inhibitors for the treatment of breast cancer: an update, anticancer agent', 'volume': '14', 'author': 'Gobbi', 'year': '2014', 'journal-title': 'Med. Chem.'} / Med. Chem. / Nonsteroidal aromatase inhibitors for the treatment of breast cancer: an update, anticancer agent by Gobbi (2014)
  67. 10.1016/j.tiv.2015.05.017 / Tox. Vitro / Structural findings of phenylindoles as cytotoxic antimitotic agents in human breast cancer cell lines through multiple validated QSAR studies by Adhikari (2015)
  68. 10.1139/cjc-2016-0050 / Can. J. Chem. / Exploring structural requirements of unconventional Knoevenagel-type indole derivatives as anticancer agents through comparative QSAR modeling approaches by Amin (2016)
  69. 10.1016/j.bmc.2016.07.023 / Bioorg. Med. Chem. / Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: syntheses and biological assays by Adhikari (2016)
  70. Tripos Inc., SYBYL-X 2.0, 1699 South Hanley Road. St Louis, MO. 63144. USA, 2012.
  71. {'key': '10.1016/j.ejmech.2017.05.041_bib71', 'series-title': 'A.\xa0Exploring QSAR: Fundamentals and Applications in Chemistry and Biology', 'author': 'Hansch', 'year': '1995'} / A. Exploring QSAR: Fundamentals and Applications in Chemistry and Biology by Hansch (1995)
  72. 10.1021/jm00158a007 / J. Med. Chem. / Aromatase inhibitors. synthesis and evaluation of mammary tumor inhibiting activity of 3-alkylated 3-(4-aminophenyl)piperidine-2,6-dione by Hartmann (1986)
  73. 10.1021/jm00392a004 / J. Med. Chem. / Analogs of 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione as selective inhibitors of aromatase: derivatives with variable 1-alkyl and 3-alkyl substituents by Leung (1987)
  74. 10.1021/jm00400a014 / J. Med. Chem. / Analogs of aminoglutethimide based on 1-phenyl-3-azabicyclo[3.1.0]hexane-2,4-dione: selective inhibition of aromatase activity by Rowlands (1988)
  75. 10.1021/jm00108a013 / J. Med. Chem. / Synthesis and aromatase inhibitory activity of novel 1-(4-aminophenyl)-3-azabicyclo[3.1.0]hexane- and -[3.1.1]heptane-2,4-diones by Stanek (1991)
  76. 10.1021/jm00098a016 / J. Med. Chem. / Conformational analysis of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione (rogletimide) and discovery of potent 5-alkyl derivatives by McCague (1992)
  77. 10.3109/14756369309020181 / J. Enz. Inhib. / Some 1-, and 3-substituted 3-(4-aminophenyl)pyrrolidine-2,5-diones as selective inhibitors of aromatase by Whomsley (1993)
  78. {'key': '10.1016/j.ejmech.2017.05.041_bib78', 'first-page': '279', 'article-title': 'Comparison of the in\xa0vitro aromatase inhibitory activity for 3- (azolylmethyl)-1H-indoles', 'volume': '3', 'author': 'Le Brogne', 'year': '1997', 'journal-title': 'Pharm. Sci.'} / Pharm. Sci. / Comparison of the in vitro aromatase inhibitory activity for 3- (azolylmethyl)-1H-indoles by Le Brogne (1997)
  79. 10.1002/ardp.19973300506 / Arch. Pharm. by Le Brogne (1997)
  80. {'key': '10.1016/j.ejmech.2017.05.041_bib80', 'first-page': '211', 'article-title': '3-(Azolylmethyl)-1H-indoles as selective P450 aromatase inhibitors', 'volume': '4', 'author': 'Marchand', 'year': '1998', 'journal-title': 'Pharm. Pharmacol. Commun.'} / Pharm. Pharmacol. Commun. / 3-(Azolylmethyl)-1H-indoles as selective P450 aromatase inhibitors by Marchand (1998)
  81. 10.1016/S0960-894X(98)00737-9 / Bioorg. Med. Chem. Lett. / New selective non-steroidal aromatase inhibitors: synthesis and inhibitory activity of 2,3 or 5-(α-azolylbenzyl)-1H-indoles by Le Brogne (1999)
  82. 10.1016/S0960-894X(03)00182-3 / Bioorg. Med. Chem. Lett. / Preparation and pharmacological profile of 7-(α-Azolylbenzyl)-1H-indoles and indolines as new aromatase inhibitors by Marchand (2003)
  83. 10.1080/14756360701652658 / J. Enz. Inhib. Med. Chem. / Synthesis and biological evaluation of 3-(azolylmethyl)-1H-indoles and 3-(alpha-azolylbenzyl)-1H-indoles as selective aromatase inhibitors by Le Brogne (2007)
  84. 10.1016/j.bmc.2012.02.042 / Bioorg. Med. Chem. Lett. / Development of a new class of aromatase inhibitors: design, synthesis and inhibitory activity of 3-phenylchroman-4-one (isoflavanone) derivatives by Bonfield (2012)
  85. 10.1007/s00894-010-0667-y / J. Mol. Model / Docking and 3D-QSAR studies of diverse classes of human aromatase (CYP19) inhibitors by Roy (2010)
  86. 10.1016/j.bmc.2010.05.042 / Bioorg. Med. Chem. / Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer by Sun (2010)
  87. 10.1080/14756360400004631 / J. Enz. Inhib. Med. Chem. / 2- and 3-[(aryl)(azolyl)methyl]indoles as potential non-steroidal aromatase inhibitors by Leze (2004)
  88. 10.1016/j.bmcl.2005.11.099 / Bioorg. Med. Chem. Lett. / Synthesis and biological evaluation of 5-[(aryl)(1H-imidazol-1-yl)methyl]-1H-indoles: potent and selective aromatase inhibitors by Leze (2006)
  89. 10.1016/j.bmcl.2008.06.094 / Bioorg. Med. Chem. Lett. / Synthesis of 6- or 4-functionalized indoles via a reductive cyclization approach and evaluation as aromatase inhibitors by Leze (2008)
  90. 10.1016/j.bmcl.2013.01.045 / Bioorg. Med. Chem. Lett. / Design, synthesis and aromatase inhibitory activities of novel indole-imidazole derivatives by Wang (2013)
  91. 10.1002/ardp.2503241008 / Arch. Pharm. Weinh. / Pyridyl-substituted tetralone derivatives: a new class of non-steroidal aromatase inhibitors by Hartmann (1991)
  92. 10.1002/ardp.2503241102 / Arch. Pharm. Weinh. / New inhibitors of aromatase: synthesis and biological activity of pyridyl-substituted phenanthrenone derivatives by Hartmann (1991)
  93. 10.1021/jm00113a004 / J. Med. Chem. / New aromatase inhibitors. synthesis and biological activity of pyridyl-substituted tetralone derivatives by Bayer (1991)
  94. 10.1021/jm00035a007 / J. Med. Chem. / Aromatase inhibitors. syntheses and structure-activity studies of novel pyridyl-substituted indanones, indans, and tetralins by Hartmann (1994)
  95. 10.1021/jm00012a009 / J. Med. Chem. / Pyridyl-substituted tetrahydrocyclopropa[a]naphthalenes: highly active and selective inhibitors of P450 arom by Hartmann (1995)
  96. 10.1021/jm950377t / J. Med. Chem. / Tetrahydronaphthalenes:  influence of heterocyclic substituents on inhibition of steroidogenic enzymes P450 arom and P450 17 by Wachter (1996)
  97. 10.1080/1475636042000196222 / J. Enz. Inhib. Med. Chem. / CYP 17 and CYP 19 inhibitors. Evaluation of fluorine effects on the inhibiting activity of regioselectively fluorinated 1-(Naphthalene-2-ylmethyl)imidazoles by Hartmann (2004)
  98. 10.1021/jm0492397 / J. Med. Chem. / Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives:  potent and selective inhibitors of aldosterone synthase by Ulmschneider (2005)
  99. 10.1021/jm049600p / J. Med. Chem. / Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes:  potent inhibitors of aldosterone synthase by Ulmschneider (2005)
  100. 10.1021/jm0503704 / J. Med. Chem. / Heteroaryl-substituted naphthalenes and structurally modified derivatives:  selective inhibitors of cyp11b2 for the treatment of congestive heart failure and myocardial fibrosis by Voets (2005)
  101. 10.1021/jm060055x / J. Med. Chem. / Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes:  potent and selective inhibitors of aldosterone synthase (cyp11b2) for the treatment of congestive heart failure and myocardial fibrosis by Voets (2006)
  102. 10.1021/jm00173a022 / J. Med. Chem. / Inhibition of enzymes of estrogen and androgen biosynthesis by esters of 4-pyridylacetic acid by McCague (1990)
  103. 10.1021/jm00021a008 / J. Med. Chem. / Esters of 3-pyridylacetic acid that combine potent inhibition of 17.alpha.-hydroxylase/c17,20-lyase (cytochrome p45017.alpha.) with resistance to esterase hydrolysis by Rowlands (1995)
  104. 10.1016/S0304-3835(98)00211-0 / Cancer Lett. / Aromatase and 17β-hydroxysteroid dehydrogenase inhibition by flavonoids by Le Bail (1998)
  105. 10.1021/np010288l / J. Nat. Prod. / Aromatase inhibitors from Broussonetia papyrifera by Lee (2001)
  106. 10.1016/S0024-3205(00)00974-7 / Life Sci. / Chalcones are potent inhibitors of aromatase and 17beta-hydroxysteroid dehydrogenase activities by Le Bail (2001)
  107. 10.1021/jm000955s / J. Med. Chem. / A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase by Recanatini (2001)
  108. {'key': '10.1016/j.ejmech.2017.05.041_bib108', 'first-page': '286', 'article-title': 'Synthesis and aromatase inhibitory activity of flavanones', 'volume': '19', 'author': 'Pouget', 'year': '2002', 'journal-title': 'J.\xa0Pharm. Res.'} / J. Pharm. Res. / Synthesis and aromatase inhibitory activity of flavanones by Pouget (2002)
  109. 10.1021/jm0306024 / J. Med. Chem. / Synthesis and aromatase inhibitory activity of novel pyridine-containing isoflavones by Kim (2004)
  110. 10.1021/jm049535j / J. Med. Chem. / Design, synthesis, and 3D QSAR of novel potent and selective aromatase inhibitors by Leonetti (2004)
  111. 10.1016/j.bmc.2005.03.050 / Bioorg. Med. Chem. / Synthesis and characterization of azole isoflavone inhibitors of aromatase by Hackett (2005)
  112. B. Su, J. C. Hackett, E. S. Diaz-Cruz, Y. W. Kim, R. W. Brueggemeier, Lead optimization of 7-benzyloxy 2-(4'-pyridylmethyl)thio isoflavone aromatase inhibitors, Bioorg. Med. Chem. 13(23) 6571–6577. (10.1016/j.bmc.2005.07.038)
  113. 10.1021/jm060186y / J. Med. Chem. / Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme by Gobbi (2006)
  114. 10.1021/jm070109i / J. Med. Chem. / Synthesis and biological evaluation of (±)-abyssinone ii and its analogues as aromatase inhibitors for chemoprevention of breast cancer by Maiti (2007)
  115. 10.1016/j.bmc.2007.10.057 / Bioorg. Med. Chem. / New 7,8-benzoflavanones as potent aromatase inhibitors: synthesis and biological evaluation by Yahiaoui (2008)
  116. 10.1021/jm801335z / J. Med. Chem. / Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities by Maiti (2009)
  117. 10.1021/jm100319h / J. Med. Chem. / Novel highly potent and selective nonsteroidal aromatase inhibitors: synthesis, biological evaluation and structure-activity relationships investigation by Gobbi (2010)
  118. 10.1021/jm101120u / J. Med. Chem. / Design, synthesis, and biological evaluation of imidazolyl derivatives of 4,7-disubstituted coumarins as aromatase inhibitors selective over 17-α-hydroxylase/C17-20 lyase by Stefanchi (2011)
  119. 10.1021/jm301844q / J. Med. Chem. / Modulation of cytochromes P450 with xanthone-based molecules: from aromatase to aldosterone synthase and steroid 11β-hydroxylase inhibition by Gobbi (2013)
  120. 10.1016/j.bmc.2013.11.045 / Bioorg. Med. Chem. / Investigation of fluorinated and bifunctionalized 3-phenylchroman-4-one (isoflavanone) aromatase inhibitors by Amato (2014)
  121. 10.1016/j.ejmech.2014.10.021 / Eur. J. Med. Chem. / Discovery of new 7-substituted-4-imidazolylmethyl coumarins and 4'-substituted-2-imidazolyl acetophenones open analogues as potent and selective inhibitors of steroid-11β-hydroxylase by Stefanchi (2015)
  122. 10.1016/j.tet.2015.06.058 / Tetrahedron / Cytotoxic and cancer chemopreventive properties of prenylated stilbenoids from Macaranga siamensis by Pailee (2015)
  123. 10.1021/jm991180u / J. Med. Chem. / 1-imidazolyl(alkyl)-substituted di- and tetrahydroquinolines and analogues: syntheses and evaluation of dual inhibitors of thromboxane A(2) synthase and aromatase by Jacobs (2000)
  124. 10.1021/jm3004637 / J. Med. Chem. / Selective dual inhibitors of CYP19 and CYP11B2: targeting cardiovascular diseases hiding in the shadow of breast cancer by Hu (2012)
  125. 10.1021/jm301408t / J. Med. Chem. / Tetrahydropyrroloquinolinone type dual inhibitors of aromatase/aldosterone synthase as a novel strategy for breast cancer patients with elevated cardiovascular risks by Yin (2013)
  126. 10.1021/jm400377z / J. Med. Chem. / Design, synthesis, and structure-activity relationships of azolylmethylpyrroloquinolines as non-steroidal aromatase inhibitors by Ferlin (2013)
  127. 10.1002/mnfr.201100122 / Mol. Nutr. Food Res. / Resveratrol derivatives as promising chemopreventive agents with improved potency and selectivity by Kondratyuk (2011)
  128. 10.1016/j.bmc.2011.09.031 / Bioorg. Med. Chem. / Optimizing thiadiazole analogues of resveratrol versus three chemopreventive targets by Mayhoub (2012)
  129. 10.1016/j.bmc.2012.01.047 / Bioorg. Med. Chem. / Optimization of the aromatase inhibitory activities of pyridylthiazole analogues of resveratrol by Mayhoub (2012)
  130. 10.1211/0022357991772637 / J. Pharm. Pharmacol. / Inhibition of aromatase (P450Arom) by some 1-(benzofuran-2-ylmethyl)imidazoles by Owen (1999)
  131. {'key': '10.1016/j.ejmech.2017.05.041_bib131', 'first-page': '217', 'article-title': '1-[(Benzofuran-2-yl)phenylmethyl]triazoles as steroidogenic inhibitors: synthesis and in\xa0vitro inhibition of human placental CYP19 aromatase', 'volume': '16', 'author': 'Vinh', 'year': '2001', 'journal-title': 'Anti-Can. Drug Des.'} / Anti-Can. Drug Des. / 1-[(Benzofuran-2-yl)phenylmethyl]triazoles as steroidogenic inhibitors: synthesis and in vitro inhibition of human placental CYP19 aromatase by Vinh (2001)
  132. 10.1021/jm0508282 / J. Med. Chem. / Potent CYP19 (aromatase) 1-[(benzofuran-2-yl)(phenylmethyl)pyridine, -imidazole, and -triazole inhibitors: synthesis and biological evaluation by Saberi (2006)
  133. 10.1002/cmdc.200700266 / ChemMedChem / Non-steroidal aromatase inhibitors based on a biphenyl scaffold: synthesis, in vitro SAR, and molecular modelling by Jackson (2008)
  134. 10.1021/jm901705h / J. Med. Chem. / Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template by Woo (2010)
  135. 10.1021/jm100400a / J. Med. Chem. / Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors by Hu (2010)
  136. 10.1021/jm100317b / J. Med. Chem. / Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer by Hu (2010)
  137. 10.1021/jm051126f / J. Med. Chem. / Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition by Su (2006)
  138. 10.1021/jm061133j / J. Med. Chem. / Synthesis and biological evaluation of selective aromatase expression regulators in breast cancer cells by Su (2007)
  139. 10.1021/jm701107h / J. Med. Chem. / Novel sulfonanilide analogs decrease aromatase activity in breast cancer cells: synthesis, biological evaluation, and ligand-based pharmacophore identification by Su (2008)
  140. 10.1021/jm00391a016 / J. Med. Chem. / Aromatase inhibition by 5-substituted pyrimidines and dihydropyrimidines by Taylor (1987)
  141. 10.1021/jm00163a065 / J. Med. Chem. / Estrogen synthetase inhibitors. 2. Comparison of the in vitro aromatase inhibitory activity for a variety of nitrogen heterocycles substituted with diarylmethane or diarylmethanol groups by Jones (1990)
  142. 10.1039/b707768h / Org. Biomol. Chem. / Dual aromatase-sulfatase inhibitors based on the anastrozole template: synthesis, in vitro SAR, molecular modelling and in vivo activity by Jackson (2007)
  143. 10.1021/jm061462b / J. Med. Chem. / Dual aromatase-steroid sulfatase inhibitors by Woo (2007)
  144. 10.1002/cmdc.200800164 / ChemMedChem. / Synthesis of aromatase inhibitors and dual aromatase steroid sulfatase inhibitors by linking an arylsulfamate motif to 4-(4H-1,2,4-triazol-4-ylamino) benzonitrile: SAR, crystal structures, in vitro and in vivo activities by Bubert (2008)
  145. 10.1021/jm800168s / J. Med. Chem. / Chiral aromatase and dual aromatase-steroid sulfatase inhibitors from the letrozole template: synthesis, absolute configuration, and in vitro activity by Wood (2008)
  146. 10.1002/cmdc.201000203 / ChemMedChem. / Bicyclic derivatives of the potent dual aromatase-steroid sulfatase inhibitor 2-Bromo-4-{[(4-cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenylsulfamate: synthesis, SAR, crystal structure, and in vitro and in vivo activities by Wood (2010)
  147. 10.1021/ml100273k / ACS Med. Chem. Lett. / Hybrid dual aromatase-steroid sulfatase inhibitors with exquisite picomolar inhibitory activity by Woo (2011)
  148. 10.1002/cmdc.201100145 / ChemMedChem. / Aromatase and dual aromatase-steroid sulfatase inhibitors from the letrozole and vorozole templates by Wood (2011)
  149. 10.1002/cmdc.201300015 / ChemMedChem. / Synthesis and structure-activity relationship studies of derivatives of the dual aromatase-sulfatase inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate by Woo (2011)
  150. 10.1021/jm00106a038 / J. Med. Chem. / Fadrozole hydrochloride: a potent, selective, non-steroidal inhibitor of aromatase for the treatment of estrogen-dependent disease by Browne (1991)
  151. 10.1021/jm00062a012 / J. Med. Chem. / Aromatase inhibitors: synthesis, biological activity, and binding mode of azole-type compounds by Furet (1993)
  152. 10.1016/S0928-0987(00)00074-9 / Eur. J. Pharm. Sci. / Synthesis of new potent and selective aromatase inhibitors based on long-chained diarylalkylimidazole and diarylalkyltriazole molecule skeletons by Karjalainen (2000)
  153. 10.1021/jm020557k / J. Med. Chem. / Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors by Nakamura (2003)
  154. 10.1021/jm0702938 / J. Med. Chem. / Imidazolylmethylbenzophenones as highly potent aromatase inhibitors by Gobbi (2007)
  155. 10.1016/j.ejmech.2011.05.074 / Eur. J. Med. Chem. / Synthesis and structure-activity relationship of 1- and 2-substituted-1,2,3-triazole letrozole-based analogues as aromatase inhibitors by Doiron (2011)
  156. 10.1021/jm2000689 / J. Med. Chem. / Structure-based design of potent aromatase inhibitors by high-throughput docking by Caporuscio (2011)
  157. 10.1021/jm950749y / J. Med. Chem. / 3- and 4-pyridylalkyl adamantanecarboxylates: inhibitors of human cytochrome P450(17 alpha) (17 alpha-hydroxylase/C17,20-lyase). Potential non-steroidal agents for the treatment of prostatic cancer by Chan (1996)
  158. 10.1016/j.bmcl.2012.01.076 / Bioorg. Med. Chem. Lett. / New aromatase inhibitors from the 3-pyridyl arylether and 1-aryl pyrrolo[2,3-c]pyridine series by Stauffer (2012)
  159. 10.1016/j.ejmech.2015.04.013 / Eur. J. Med. Chem. / Identification of 4-(4-nitro-2-phenethoxyphenyl) pyridine as a promising new lead for discovering inhibitors of both human and rat 11β-Hydroxylase by Hu (2015)
  160. 10.1016/j.bmc.2015.04.036 / Bioorg. Med. Chem. / Synthesis and molecular docking of 1,2,3-triazole-based sulfonamides as aromatase inhibitors by Pingaew (2015)
  161. 10.1021/jm501218e / J. Med. Chem. / Design and synthesis of norendoxifen analogues with dual aromatase inhibitory and estrogen receptor modulatory activities by Lv (2015)
  162. 10.1016/j.bmc.2005.05.002 / Bioorg. Med. Chem. / An approach toward the problem of outliers in QSAR by Verma (2005)
  163. 10.1021/cr020464a / Chem. Rev. / Cyclooxygenase (COX) inhibitors: a comparative QSAR study by Garg (2003)
  164. 10.1038/sj.bjp.0707305 / Br. J. Pharmacol. / In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling by Ekins (2007)
  165. 10.1021/ci050314b / J. Chem. Inf. Model / Modeling robust QSAR by Polanski (2006)
Dates
Type When
Created 8 years, 3 months ago (May 31, 2017, 4:45 a.m.)
Deposited 1 year, 2 months ago (June 24, 2024, 8:54 a.m.)
Indexed 1 month ago (Aug. 2, 2025, 1:24 a.m.)
Issued 8 years ago (Sept. 1, 2017)
Published 8 years ago (Sept. 1, 2017)
Published Print 8 years ago (Sept. 1, 2017)
Funders 1
  1. UGC 10.13039/501100001501 University Grants Commission

    Region: Asia

    gov (Universities (academic only))

    Labels6
    1. UGC INDIA
    2. University Grants Commission (India)
    3. विश्वविद्यालय अनुदान आयोग
    4. University Grants Commission India
    5. UGC
    6. यूजीसी
    Awards1
    1. F1-17.1/2014-15/RGNF-2014-15-SC-WES-73725/SA-III/Website

@article{Adhikari_2017, title={Combating breast cancer with non-steroidal aromatase inhibitors (NSAIs): Understanding the chemico-biological interactions through comparative SAR/QSAR study}, volume={137}, ISSN={0223-5234}, url={http://dx.doi.org/10.1016/j.ejmech.2017.05.041}, DOI={10.1016/j.ejmech.2017.05.041}, journal={European Journal of Medicinal Chemistry}, publisher={Elsevier BV}, author={Adhikari, Nilanjan and Amin, Sk. Abdul and Saha, Achintya and Jha, Tarun}, year={2017}, month=sep, pages={365–438} }